Quantitative Standard for Hepatitis B Virus DNA

Quantitative hepatitis B virus (HBV) DNA testing is a critical indicator for screening HBV infection and evaluating the efficacy of antiviral therapy, as well as an essential reference for formulating antiviral treatment plans. So, what constitutes the standard for quantitative HBV DNA testing? Below, we provide a detailed explanation.

Standard Values for Quantitative HBV DNA Testing

In clinical practice, different healthcare institutions use reagents from various manufacturers to perform fluorescent quantitative HBV DNA testing; consequently, their reference value ranges differ. Commonly accepted “normal” or “undetectable” thresholds include: <1000 IU/mL, <500 IU/mL, <100 IU/mL, and <50 IU/mL. A few institutions still report results in copies/mL. Currently, the most sensitive and precise detection method is the Cobas assay—also known as high-sensitivity testing—with a cutoff value of <20 IU/mL. Most domestic institutions utilize locally manufactured reagents, with typical thresholds set at <500 IU/mL. Some specialized hepatology centers employ more sensitive methodologies, yielding thresholds often below <100 IU/mL. When Roche (imported) reagents are used, the assay sensitivity increases further, with a cutoff of <20 IU/mL. Therefore, quantitative standards vary depending on the reagent employed by each institution.

Knowledge Extension: Clinical Significance of Quantitative HBV DNA Standards

1. One Criterion for Initiating Treatment

According to China’s Guidelines for Antiviral Therapy of Chronic Hepatitis B, antiviral treatment is generally not recommended when HBV DNA levels fall below 2000 IU/mL. Only when HBV DNA levels reach or exceed this threshold—and in conjunction with repeated liver function test results—should a rational antiviral treatment regimen be initiated.

2. Assessment of Infectivity

Routine hepatitis B serology (“two-and-a-half” panel) can determine whether HBV infection is present and assess viral replication status. However, it cannot quantify viral load, thus providing only limited insight into infectivity. In contrast, quantitative HBV DNA testing offers precise numerical data reflecting infectious potential. An HBV DNA level below the assay’s lower limit of detection indicates negligible or no infectivity.

3. Evaluation of Treatment Response

During antiviral therapy for hepatitis B, a rapid decline in HBV DNA levels typically indicates favorable drug response, warranting continuation of the current regimen. Conversely, if HBV DNA declines by less than 1% within six months, the response is considered suboptimal, necessitating modification of the treatment strategy.

4. Prediction of Disease Progression

Combined with hepatitis B serology results, quantitative HBV DNA testing helps effectively predict disease progression in chronic carriers—particularly the risk of developing hepatic fibrosis or cirrhosis. For instance, if hepatitis B e-antigen (HBeAg) is negative and HBV DNA remains consistently below the clinical detection threshold, viral load is low and replication is minimal; in such cases, treatment is usually unnecessary.

The above outlines key aspects of quantitative HBV DNA standards. We hope this information proves helpful.